Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.42 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 8/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 7/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.40 |
| ▸ | ACVRL1 | P37023 | 10/20 | 0.40 |
| ▸ | ACVR1 | Q04771 | 10/20 | 0.40 |
| ▸ | BMPR1A | P36894 | 9/20 | 0.40 |
| ▸ | BMPR1B | O00238 | 8/20 | 0.40 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
| ▸ | PRF1 | P14222 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL750180 | 0.86 | CYP11B1 (0.41) | CYP11B2CYP11B1CYP1A2ACVRL1ACVR1 | |
| SCHEMBL768493 | 0.86 | CYP11B1 (0.41) | CYP11B2CYP11B1CYP1A2ACVRL1ACVR1 | |
| SCHEMBL769004 | 0.84 | CYP11B2 (0.44) | PARP10PARP11CYP11B2CYP11B1CYP17A1 | |
| SCHEMBL769159 | 0.83 | CYP11B1 (0.41) | CYP11B2CYP11B1CYP1A2ACVRL1ACVR1 | |
| SCHEMBL768752 | 0.82 | PARP10 (0.41) | PARP10PARP11CYP11B2CYP11B1ACVRL1 | |
| SCHEMBL749006 | 0.81 | CYP11B2 (0.54) | PARP10PARP11CYP11B2CYP11B1CYP1A2 | |
| SCHEMBL777590 | 0.80 | ACVR1 (0.36) | CYP11B2CYP11B1CYP1A2ACVRL1ACVR1 | |
| SCHEMBL769108 | 0.75 | CYP11B1 (0.34) | CYP11B2CYP11B1CYP1A2ACVRL1ACVR1 | |
| SCHEMBL745958 | 0.74 | ACVRL1 (0.67) | CYP11B2CYP11B1ACVRL1ACVR1BMPR1A | |
| SCHEMBL768797 | 0.73 | CYP11B1 (0.48) | PARP10PARP11CYP11B2CYP11B1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140275175-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2014-09-18 | — | — | US | disclosed |
| US-20140275175-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2014-09-18 | — | — | US | disclosed |
| US-8778972-B2 | 5-pyridin-3-yl-1, 3-dihydro-indol-2-on derivatives and their use as modulators of aldosterone synthase and/or CYP11B1 | NOVARTIS AG (CH) | 2014-07-15 | — | — | US | disclosed |
| US-20120071512-A1 | 5-PYRIDIN-3-YL-1, 3-DIHYDRO-INDOL-2-ON DERIVATIVES AND THEIR USE AS MODULATORS OF ALDOSTERONE SYNTHASE AND/OR CYP11B1 | NOVARTIS AG (CH) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275175-A1 | ORGANIC COMPOUNDS | CYP11B2, CYP11B1, SLCO1B1 | PARP10 2258/4885PARP11 1840/4885CYP11B2 1/4885 |
| US-20120071512-A1 | 5-PYRIDIN-3-YL-1, 3-DIHYDRO-INDOL-2-ON DERIVATIVES AND THEIR USE AS MODULATORS OF ALDOSTERONE SYNTHASE AND/OR CYP11B1 | CYP11B1, HSD11B1, CYP11B2 | PARP10 1356/4885PARP11 543/4885CYP11B2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.